Zacks Investment Research cut shares of Nabriva Therapeutics AG (NASDAQ:NBRV) from a hold rating to a sell rating in a report issued on Wednesday morning.
According to Zacks, “Nabriva Therapeutics AG is a biopharmaceutical company. The Company is involved in the research and development of novel anti-infective agents to treat serious infections, which focus on the pleuromutilin class of antibiotics. Its product candidate consists of BC-3781, developed for the treatment of serious skin infections and bacterial pneumonia caused by MRSA and other drug resistant bacteria; BC-7013, a topical pleuromutilin antibiotic which are in different clinical trial. Nabriva Therapeutics AG is based in Vienna, Austria. “
NBRV has been the topic of several other reports. Needham & Company LLC reaffirmed a buy rating and set a $15.00 target price on shares of Nabriva Therapeutics AG in a report on Monday, March 27th. Cantor Fitzgerald reaffirmed a buy rating and set a $16.00 target price on shares of Nabriva Therapeutics AG in a report on Tuesday, April 11th. HC Wainwright reaffirmed a buy rating on shares of Nabriva Therapeutics AG in a report on Friday, May 12th. Wedbush reaffirmed an outperform rating and set a $13.00 target price on shares of Nabriva Therapeutics AG in a report on Monday, May 15th. Finally, ValuEngine raised Nabriva Therapeutics AG from a sell rating to a hold rating in a report on Saturday, June 24th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company’s stock. The company currently has an average rating of Buy and a consensus price target of $15.29.
Shares of Nabriva Therapeutics AG (NBRV) opened at 10.35 on Wednesday. The firm’s 50 day moving average price is $9.87 and its 200-day moving average price is $9.52. Nabriva Therapeutics AG has a 1-year low of $3.52 and a 1-year high of $12.75. The company’s market capitalization is $28.16 million.
In other news, Director George Harrison Talbot sold 325 shares of the firm’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $100.56, for a total value of $32,682.00. Following the transaction, the director now owns 3,854 shares in the company, valued at $387,558.24. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Hbm Healthcare Investments (Ca sold 23,932 shares of the firm’s stock in a transaction that occurred on Thursday, April 20th. The shares were sold at an average price of $11.11, for a total value of $265,884.52. Following the completion of the transaction, the insider now owns 2,624,633 shares in the company, valued at approximately $29,159,672.63. The disclosure for this sale can be found here. Insiders have sold 126,778 shares of company stock worth $1,453,057 in the last quarter.
Several institutional investors have recently added to or reduced their stakes in the stock. Almanack Investment Partners LLC. purchased a new position in Nabriva Therapeutics AG during the first quarter valued at $1,870,000. Wellington Management Group LLP increased its position in Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock valued at $25,830,000 after buying an additional 193,951 shares during the period. Nationwide Fund Advisors purchased a new position in Nabriva Therapeutics AG during the first quarter valued at $2,074,000. Finally, Renaissance Technologies LLC purchased a new position in Nabriva Therapeutics AG during the fourth quarter valued at $103,000. Institutional investors and hedge funds own 56.73% of the company’s stock.
Nabriva Therapeutics AG Company Profile
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic for systemic administration in humans. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.